Overview

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
Trans Tech Pharmaceuticals